2′-C-methyl-3′-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
View Patent ↗The 3′-L-valine ester of β-D-2′-C-methyl-ribofuranosyl cytidine provides superior results against flaviviruses and pestiviruses, including hepatitis C virus. Based on this discovery, compounds, compositions, methods and uses are provided for the treatment of flaviviridae, including HCV, that include the administration of an effective amount of val-mCyd or its salt, ester, prodrug or derivative, optionally in a pharmaceutically acceptable carrier. In an alternative embodiment, val-mCyd is used to treat any virus that replicates through an RNA-dependent RNA polymerase.
1. A method of treating a host infected with a Flaviviridae virus, comprising administering to the host an effective amount of a compound having the structure of the formula:
or a pharmaceutically acceptable salt or prodrug thereof optionally in a pharmaceutically acceptable carrier.
2. The method according to claim 1 , wherein the pharmaceutically acceptable salt is a hydrochloride salt.
3. The method according to claim 1 , wherein the pharmaceutically acceptable salt is a dihydrochloride salt.
4. The method according to claim 1 , further comprising administering the compound in a pharmaceutically acceptable carrier, diluent or excipient.
5. The method according to claim 1 , wherein the compound is administered in combination or alternation with a second anti-viral agent.
6. The method according to claim 5 , wherein the second antiviral agent is selected from the group consisting of an interferon, ribavirin, an interleukin, a NS3 protease inhibitor, a cysteine protease inhibitor, thiazolidine derivative, thiazolidine, benzanilide, phenan-threnequinone, a helicase inhibitor, a polymerase inhibitor, a nucleoside analogue, gliotoxin, cerulenin, antisense phosphorothioate oligodeoxynucleotides, an inhibitor of IRES-dependent translation, and a ribozyme.
7. The method according to claim 5 , wherein the second antiviral agent is an interferon.
8. The method according to claim 7 , wherein the second agent is selected from the group consisting of pegylated interferon alpha 2a, interferon alphacon-1, natural interferon, albuferon, interferon beta-1a, omega interferon, interferon alpha, interferon gamma, interferon tau, interferon delta and interferon gamma-1b.
9. The method of claim 8 , wherein the second antiviral agent is interferon alpha 2.
10. The method of claim 1 , wherein the host is a human.
11. The method of claim 1 , wherein the compound is in the form of a dosage unit.
12. The method of claim 11 , wherein the dosage unit contains 70 to 1400 mg of the compound.
13. The method of claim 11 , wherein the dosage unit is a tablet or capsule.
14. The method of any one of claims 1 - 3 , wherein the pharmaceutically acceptable carrier is suitable for oral or intravenous delivery.
15. The method of any one of claims 1 - 3 , wherein the compound is administered in substantially pure form.
16. The method of any one of claims 1 - 3 , wherein the compound is at least 90% by weight of the β-D-isomer.
17. The method of any one of claims 1 - 3 , wherein the compound is at least 95% by weight of the β-D-isomer.
18. The method of any one of claims 1 - 3 , wherein the virus is hepatitis C.
19. A method for treating a host infected with an RNA-dependant RNA polymerase virus, comprising administering an effective amount of the compound of the formula:
or its mono or dihydrochloride in pharmaceutically acceptable carrier, wherein the 5′-hydroxyl group is replaced with a 5′-OR, wherein R is hydrogen, phosphate; a stabilized phosphate prodrug; acyl; an amino acid; a carbohydrate; a peptide; or other pharmaceutically acceptable leaving group which when administered in viva provides a compound wherein R is independently H or phosphate.
20. The method of claim 19 wherein the virus is a F/aviviridae virus.
21. The method of claim 19 or 20 wherein the Flaviviridae virus is hepatitis C.
22. The method of claim 19 or 20 wherein the host is a human.
23. The method of claim 1 , wherein the pharmaceutically acceptable salt is selected from tosylate, methanesulfonate, acetate, citrate, malonate, tartarate, succinate, benzoate, ascorbate, α-ketoglutarate, and α-glycerophosphate, formate, fumarate, propionate, glycolate, lactate, pyruvate, oxalate, maleate, salicyate, sulfate, sulfonate, nitrate, hydrobromate, hydrobromide, hydroiodide, and phosphoric acid salts.
24. The method of claim 19 , wherein the compound or a pharmaceutically acceptable salt thereof, is administered in combination with a pharmaceutically acceptable carrier.
25. The method of claim 24 , wherein the carrier is suitable for oral or intravenous delivery.
26. The method of claim 19 , wherein the compound is in the form of a dosage unit.
27. The method of claim 19 , wherein the compound is administered in substantially pure form.
28. The method of claim 19 , wherein the compound is at least 90% by weight of the β-D-isomer.
29. The method of claim 19 , wherein the compound is at least 95% by weight of the β-D-isomer.
30. The method of claim 11 or 26 , wherein the dosage unit contains 50 mg to 1000 mg of the compound.
31. The method of claim 11 or 26 , wherein the dosage unit contains 100 mg of the compound.
32. The method of claim 11 or 26 , wherein the dosage unit contains 200 mg of the compound.
33. The method of claim 11 or 26 , wherein the dosage unit contains 400 mg of the compound.
34. The method of claim 11 or 26 , wherein the dosage unit contains 800 mg of the compound.
35. The method of claim 11 or 26 , wherein the dosage unit contains 1000 mg of the compound.
36. The method of claim 21 wherein the host is a human.